Cuál es el precio por Aerpio Pharmaceuticals, Inc. (ARPO)

Precio por Aerpio Pharmaceuticals, Inc. (ARPO) es de$2.20

Cuál es la capitalización de mercado por Aerpio Pharmaceuticals, Inc. (ARPO)

Capitalización de mercado por Aerpio Pharmaceuticals, Inc. (ARPO) es $40.53M

Aerpio Pharmaceuticals, Inc. (ARPO) Ratio P/B

Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in Blue Ash, Ohio, currently employs 27 full-time staff. The company's core mission revolves around the research and development of therapeutic solutions for ocular diseases. Its product pipeline is spearheaded by AKB-9778, with two additional programs, AKB-4924 and ARP-1536, also under development. AKB-9778 is a small molecule designed to activate the Tie-2 pathway, intended for the treatment of diabetic retinopathy (DR). AKB-4924, another candidate, functions as a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) and is being investigated for its potential in treating inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody that targets the same pathway as AKB-9778. It operates by attaching to the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP), thereby inhibiting its interaction with Tie-2. As of April 14, 2017, Aerpio had successfully concluded a Phase II clinical trial for AKB-9778, which involved 144 patients with diabetic macular edema. By the same date, a Phase Ia clinical trial for AKB-4924 in healthy volunteers had also been completed.

Año	Ratio P/B	Cambiar
Not enough data for the provided dates.

Año

Ratio P/B

Cambiar

Not enough data for the provided dates.

Empresa	Ratio P/B	Diferencia del ratio P/B	País
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	3.7087	-	US

Empresa

Ratio P/B

Diferencia del ratio P/B

País